MedTrace Logo

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NCT01328821 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2011-10-26

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

CTP-499

600 mg, 1200 mg, 1800 mg and 2400 mg

DRUG

CTP-499

400 mg immediate release capsule

Sponsors & Collaborators

  • Concert Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gregory Tracey, MD · Frontage Clinical Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-04-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01328821 on ClinicalTrials.gov